Log In
Thursday 27th October 2016

NICE rapped for drug restrictions

3rd August 2006

The National Institute for Health and Clinical Excellence (NICE) is under fire over its decisions to restrict a range of drugs used to treat Alzheimer’s disease.

NICE heard five appeals over two days from campaign groups and drug companies over limiting medicines for treating moderate stages of the condition.

The drugs include donepezil, rivastigmine, and galantamine, and memantine, which is not recommended for use outside clinical trials.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

M3 - For secure managed hosting over N3 or internet
© Mayden Foundation 2016